Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Net debt / EBITDA

Net debt / EBITDA at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-6×—
Zymeworks logo
ZymeworksZYME
-0.3×—
Quest Diagnostics logo
Quest DiagnosticsDGX
2.8×-0.6×
AbbVie logo
AbbVieABBV
2.5×—
Amgen logo
AmgenAMGN
3.7×-0.7×
TG Therapeutics logo
TG TherapeuticsTGTX
2.1×+0.1×

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Calculated from ADMA Biologics’s reported figures.

net debt/ebitda=0.3×

Based on the most recent quarter.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's net debt / EBITDA?
ADMA Biologics (ADMA) reported net debt / EBITDA of 0.3× in Q1 2026.
How has ADMA Biologics's net debt / EBITDA changed year-over-year?
ADMA Biologics's net debt / EBITDA increased by 176.5% year-over-year, from -0.4× to 0.3×.
What is the long-term trend for ADMA Biologics's net debt / EBITDA?
Over 2 years (2023 to 2025), ADMA Biologics's net debt / EBITDA has grown at a -83.2% compound annual growth rate (CAGR), from -1.4× to -0×.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.